What Happens When You Stop a GLP-1? Understanding Weight Regain


Stopping is a medical decision, not a moral one
Coming off a GLP-1 is a clinical choice with a predictable physiology, not a test of willpower. The appetite signals the medication quieted come back when the drug clears. For most people, that means hunger rises and weight follows. Knowing this in advance lets you and your physician plan the exit instead of being surprised by it. Individual results vary.
Weight regain after stopping is the expected response of a treated chronic condition. It is what the research predicts. It happens to people with strong habits and people without them. So the goal is not to feel bad about it. The goal is to understand it well enough to make a calm decision.
Weight tends to return because a GLP-1 manages a chronic condition rather than curing it. The medication mimics a gut hormone that signals fullness and slows digestion. Stop the medication, and that signal fades. Hunger and food cues climb back toward where they started, so intake rises and the scale follows. Individual results vary.
Your body defends a "set point," a weight range it treats as home. When you lose weight, it fights to get back by raising appetite hormones and lowering the calories you burn at rest. The medication counteracts that push while you take it. Remove the counterweight, and the old pressure returns. That is physiology, not a flaw in you.
The withdrawal data, read honestly
The strongest evidence on stopping comes from trials that deliberately took the medication away and watched what happened. Two stand out. They tell a consistent story, and reading them without scare framing matters. Regain is common, it is partial in most cases, and continued treatment changes the curve. Individual results vary.
In the 327-person STEP 1 extension subset, participants originally assigned semaglutide lost a mean 17.3% over 68 weeks. Medication and structured lifestyle support then ended. Over the following year they regained 11.6 percentage points, about two-thirds of the loss, leaving a mean net loss of 5.6% at week 120.
In SURMOUNT-4, adults first received tirzepatide for 36 weeks
Participants were then randomized to continue treatment or switch to placebo for 52 weeks. From week 36 to week 88, mean weight changed by -5.5% with continued tirzepatide and +14.0% with placebo using the primary treatment-regimen estimand.
The 2026 picture is shifting fast
The FDA approved orforglipron, marketed as Foundayo, as an oral weight-management option in April 2026. Suitability depends on its labeled indication and your medical history; this approval does not establish equivalence to an injectable medicine.

How fast does weight come back after stopping? For most people, appetite signals return within weeks as the medication clears, and weight trends up over the following months. The trial data tracked regain across about a year (Wilding 2022; Aronne 2024). The pace differs from person to person. Individual results vary.
The choice to stop or stay is changing because access and options are changing. Prices are moving, oral versions are arriving, and stronger medications are in trials. None of this removes the basic biology of regain. But it does mean a "stop because of cost" decision may have more alternatives in 2026 than it did a year ago. Individual results vary.
Closing thought, and three steps
Name your reason. Cost, side effects, reaching your goal, or something else. The right next step depends on which one it is.
Ask your prescriber for a plan before stopping. Withdrawal trials did not test whether tapering prevents weight regain. A follow-up plan can address your symptoms, weight, and ongoing treatment needs.
Choose a provider who makes staying or stopping easy
Full cost shown up front, a reachable physician, and cancel anytime without a phone call.
Lose weight with a plan made just for you
- Same-day doctor visits and prescriptions
- Semaglutide, tirzepatide & other GLP-1s
- FSA & HSA eligible with all plans

From price shown is the 12-month plan rate. Prices may vary.
Frequently asked questions
Was this helpful?
Keep reading
Weight Loss
Weight Loss
Weight Loss
Weight Loss
Weight Loss
Weight Loss

Sources
- Wilding JPH, et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension." Diabetes, Obesity and Metabolism, 2022. dom-pubs.onlinelibrary.wiley.com
- Current Wegovy prescribing information, including formulation-specific indications: novo-pi.com
- Aronne LJ, et al. "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial." JAMA, 2024. jamanetwork.com